MENU

Tag: Amgen

Migraine Prevention Drug Receives FDA Approval: Aimovig By Amgen Is The First Of Its Kind

Aimovig, designed for long-term migraine prevention, will now go on sale after receiving approval from the U.S. Food and Drug Administration. The drug is the first of its kind, and it could soon mean the end of chronic migraines.

Medicine May 18, 2018

Pricey Cholesterol Drug From Amgen Reduces Heart Risks, Could Cost $14000

An expensive drug manufactured by Amgen will reportedly reduce the rate of heart problems. The cost of this effective cholesterol drug, however, is more than $14,000 a year.

Medicine March 19, 2017

Amgen Cholesterol Drug And Statin Combo Reduces Plaque Buildup In Arteries Of Heart Patients

Amgen's drug Repatha can shrink artery-clogging plaques when used together with statin. The combo also leads to a significant reduction in bad cholesterol levels among heart patients.

Medicine November 16, 2016

Amgen Researchers Find Gene That May Reduce Heart Disease Risk

DeCODE genetics, an Amgen-owned company, claimed it has identified a new genetic variant involving the ASGR1 gene, a finding that can reduce heart disease risk by 35 percent.

Medicine May 19, 2016

Drug Company Amgen Launches Online Journal For Studies That Attempt To Replicate Experimental Results

Amgen pioneered in establishing a platform for failed efforts in replicating studies. This will allow companies and academic researchers to share replications to others so it will prevent them from wasting time and effort on following up flawed findings.

Life February 5, 2016

Amgen Cholesterol Drug Repatha Turned Down By UK Cost Watchdog

Amgen's Repatha has been turned down for NHS funding by NICE. The UK cost watchdog said that analyses presented for the anti-cholesterol drug exhibited a high level of uncertainty, and thus cannot be recommended for use in Britain's state health.

Life November 19, 2015

FDA Gives Approval To Amgen Melanoma Drug That Uses Herpes Virus To Fight Cancer

Amgen's Melanoma drug made history as the first drug of its kind to get an FDA approval. The drug uses a genetically engineered herpes virus to attack tumors using an immune system compound.

Life October 28, 2015

Amgen's Virus-Based Cancer Drug Wins Green Light From EU Regulators

Drug regulators from the European Medicines Agency have issued a recommendation for the approval of Amgen's virus-based cancer treatment, T-Vec. If approved by the European Commission, T-Vec would become the first drug in a class of novel agents called oncolytic immunotherapies.

Life October 24, 2015

Express Scripts Allots 750 Million To Cover Amgen And Sanofi Cholesterol Drugs

Express Scripts announced that they will be paying for Amgen and Regeneron/Sanofi's costly cholesterol drugs for their members. The company said they were able to negotiate the best prices and thus is now confident in providing the medicines under certain conditions.

Life October 8, 2015

FDA Approval Of Repatha Cholesterol Drug A Big Win For Amgen

New drug works differently from statins to lower 'bad' LDL cholesterol. Approval could bring billions into Amgen's coffers.

Life August 29, 2015

Amgen Opts To Pay $71 Million For Drug Promotion Case Settlement

Amgen Inc. decided to pay 47 states with $71 million as settlement for off-label promotions that it has been accused of for two of its products. According to the charges, the pharmaceutical company has advertised Enbrel and Aranesp outside of FDA's recommendations.

Life August 19, 2015

Amgen Cholesterol Lowering Drug Repatha Receives EU Approval

Amgen's Repatha has received the greenlight from the European Commission as treatment for those with uncontrolled cholesterol who require additional reduction in LDL.

Life July 21, 2015

New Drug May Soon Deal With Migraines Before They Even Happen

Patients with migraines may soon find relief as a new class of drug shows promising effects for the prevention of an attack even before it happens. Pharmaceutical companies have presented to the American Headache Society's annual Scientific Meeting and all of them demonstrated favorable study results.

Life June 18, 2015

FDA Panel Pushes For Approval Of Amgen's Cholesterol-Lowering Drug Repatha

Members of an FDA panel urge the agency to approve Repatha. The drug made by Amgen is said to significantly lower LDL or "bad" cholesterol.

Life June 12, 2015

New Drugs Can Lower Cholesterol But Price Might Give You A Big Headache - $10,000 A Year

PCSK9 inhibitors can lower bad cholesterol level to extremely low levels and do not come with side effects associated with statins. The new drugs, however, can cost $10,000 per year which can have significant effect on healthcare.

Life June 9, 2015

Two Powerful Cholesterol Drugs May Be Approved By Summer

By summer, Americans could be enjoying two new drugs in different doses designed to effectively lower levels of bad cholesterol in the body and improve health management.

Life May 27, 2015

Study Claims Amgen's Kyprolis More Effective Than Takeda's Velcade

In a study, Amgen drug Kyprolis outperformed Takeda’s Velcade in efficacy as treament for relapsed multiple myeloma in combination with low-dose dexamethasone.

Life March 2, 2015

Amgen Leukemia Drug Blincyto Comes with Tag Price of $178,000

For $178,000, Blincyto features a two-month treatment period. It’s definitely one of the more expensive immunotherapy cancer treatments around but Amgen counters it’s worth it.

Life December 20, 2014

Novartis Version of Amgen Cancer Drug Just as Good as Original

It’s always a good thing to have other options. Novartis’ version of Neupogen appears to be just as effective as the original, providing breast cancer patients with neutropenia other choices to consider.

Life December 8, 2014

Amgen's ovarian cancer drug trials disappoint

Ovarian cancer drug fails to improve overall survival rate in clinical trial. Amgen announces results of late-stage trial of drug trebananib.

Life November 4, 2014

Amgen's blood cancer drug successful in late-stage trial

Kyprolis, Amgen’s drug for patients with multiple myeloma, has demonstrated pharmacological benefits in its third stage of clinical trials.

Life August 5, 2014

Amgen's brodalumab improves psoriatic arthritis signs and symptoms in Phase 2 study

The new brodalumab drug from Amgen is effective in reducing the symptoms and signs of psoriatic arthritis. The effectiveness of the antibody is advocated by a new Phase 2 study.

Life June 15, 2014

New experimental cholesterol drug by Amgen may be better than Lipitor

An experimental drug developed by Amgen Inc. may soon provide an alternative and possibly even a better option for people who do not get much from taking Lipitor or cannot simply tolerate the drug.

Life April 1, 2014

Gene mutation that can reduce risk of Type 2 diabetes gets drugmakers' attention

Drug companies are already working on programs that would develop drugs based on a study which found a genetic mutation that decreases one's risks of Type 2 Diabetes.

Life March 3, 2014

Real Time Analytics